Latest news with #Mar
Time of India
5 days ago
- Entertainment
- Time of India
Zodiac Signs Who Will Experience Good Fortune in June 2025
According to Astrology, each month bring something, when it arrives. For some, it brings happiness, and for some it brings struggle. But here, we are talking about those zodiac signs who are likely to experience extreme luck in the month of June. June is coming with a lots of good things and bringing abundance for the people. June 2025 is set to be a pivotal month for few zodiac signs, as celestial alignments create chances for growth, prosperity, and personal advancement. The movement of Mars into Leo, Venus's arrival in Aries, and the Mercury in Gemini are crucial astrological occurrences that will impact these favorable changes. Here are the zodiac signs who will encounter considerable good fortune in the month of June: Taurus Taureans are receiving the universe's blessings this June, as Venus has already moved into the Aries zodiac sign on May 31, redirecting their attention towards comfort, self-worth, and enjoyment. This month emphasizes reorganizing routines for optimal pleasure and creative expression. With Mercury entering Gemini on June 6, Taureans will enhance their emotional intelligence and intuition, enabling them to navigate complex emotional situations with greater ease. Look forward to more chances for personal development, self-care, and meaningful connections. Cancer Cancerians are in for a delightful experience this June, as Jupiter transitioned into Gemini on May 14, signaling the start of a year-long enhancement of their visibility. This movement brings about growth, success, abundant fortune, and fresh opportunities. With Venus shifting into Aries through 10th house from the Cancer ascendant so these natives will find themselves with greater chances to realize their aspirations, cultivate social connections, and strengthen bonds with friends. Anticipate an increase in confidence, self-esteem, and emotional awareness. They will have a great chance to become a media person and they can choose career as influencer. Their might find the love of life at workplace. Leo Individuals born under the sign of Leo are poised to witness an increase in financial prospects as Venus transitions into their ninth house, which governs good fortune, wealth, finances and everything. During this time period, you will receive blessings from the divine feminine energy. This astrological shift is expected to introduce new sources of income and elevate their sense of self-worth. At the same time, Mar's entry in Leo on June 7 will strengthen family connections and emotional health. This timeframe is perfect for undertaking important decisions and investments related to the home. Sagittarius Sagittarians are set for an exhilarating journey this June, with Mars entering Leo on June 7, heralding the start of a significant and transformative phase in their lives. This transit offers opportunities for emotional development, spiritual discovery, and professional collaborations. With the Full Moon that fall on June 10, prepare for profound discussions regarding relationships, intimacy, and shared resources. Sagittarians will achieve clarity on who genuinely cares for their well-being and will feel empowered to make deliberate choices. These three sun signs can look forward to a notable enhancement in their fortunes this June, with chances for growth, expansion, and positive change. Keep in mind to remain receptive to new experiences, nurture your relationships, and have faith in the universe's design. Discover everything about astrology at the Times of India , including daily horoscopes for Aries , Taurus , Gemini , Cancer , Leo , Virgo , Libra , Scorpio , Sagittarius , Capricorn , Aquarius , and Pisces .
Yahoo
05-05-2025
- Business
- Yahoo
Judge throws out case against Abbott Laboratories over its preterm baby formula, days before trial was set to begin in Chicago
In a win for Abbott Laboratories, a federal judge in Chicago sided with the company Friday in the case of a woman who alleged that Abbott's formula for preterm infants led to her daughter's death. The case had been scheduled to go to trial this week, and was supposed to be the first to be heard in federal court in Chicago over the issue of whether Abbott's specialized cow's milk-based formula for preterm babies causes a life-threatening intestinal disease called necrotizing enterocolitis (NEC). North suburban-based Abbott and formula-maker Mead Johnson are facing hundreds of lawsuits in federal court in Chicago over the issue, and Abbott is facing more than 1,400 lawsuits total in courts across the country. The case dismissed Friday was a bellwether case, meaning its outcome was meant to help determine how the hundreds of other cases in federal court in Chicago proceeded, and/or how to settle those cases. The court is still scheduled to hear three other bellwether cases about the issue, with the next trial slated to begin in August. An Abbott spokesperson declined to comment Monday. An attorney for the plaintiff did not immediately respond to a request for comment Monday. In the case, Kentucky woman Ericka Mar contended that her daughter RaiLee, who was born at 28 weeks gestation in 2014, died when she was about 2 weeks old after being fed a cow's milk-based product made by Abbott. Mar alleges in her lawsuit that the formula was defective or unreasonably dangerous, that Abbott was negligent in selling it and that Abbott failed to warn health care providers and consumers of its dangers. But on Friday, U.S. District Court Judge Rebecca Pallmeyer granted Abbott's request for summary judgment and sided with the company. In her order, Pallmeyer wrote that Mar had not been able to present evidence that Abbott could have designed the formula differently to be safer, nor that her daughter's illness would have been prevented if Abbott had provided warnings about the higher risk of NEC in preterm babies who consume cow's milk-based formulas. Pallmeyer wrote that her decision in the case has 'limited direct application' to the hundreds of other cases against the formula-makers in federal court in Chicago. She wrote that it's possible plaintiffs in those other cases will be able to overcome the issues that led her to rule in favor of Abbott, depending on what evidence and testimony they provide. In a bright spot for the other cases, Pallmeyer also decided Friday to deny Abbott's request to exclude from those cases testimony from two expert witnesses on the link between cow's milk-based formulas and NEC. And she denied Abbott's motion for summary judgment in the other cases. Wells Fargo analysts said in a note Sunday that their legal consultant 'believes that it is likely that most, if not all, of the pending cases will fail on these same theories,' though it's possible different state laws might give other plaintiffs more 'breathing room,' the analysts wrote. The ruling on Friday was the latest twist in a yearslong legal battle between Abbott and families of babies who became ill after consuming the company's specialized formula for preterm infants — a battle that has potential implications for both Abbott and families with babies born very prematurely. Research has shown that formula feeding is associated with higher rates of NEC for premature infants, but that's not to say that cow's milk-based formulas cause the disease. Some premature babies who are fed only breast milk also develop NEC. Last year, three major federal agencies — the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health — released a statement saying, 'There is no conclusive evidence that preterm infant formula causes NEC.' Some medical professionals are concerned about the many cases against Abbott and Mead Johnson, saying juries should not be deciding questions that scientists can't even answer. They also worry that large verdicts against Abbott could lead the company to pull its cow's milk-based products for preterm infants off the market, leaving some families who depend on the products in a bind. Though neonatologists agree that mothers' breast milk should always be the first choice of nutrition for babies born very prematurely, it's not always available, and donated breast milk is not always an option. Abbott Chairman and CEO Robert Ford warned in an earnings call last year, 'If the regulatory process is disregarded, if the science is disregarded, it's going to be very difficult for any company to remain on the market with these products, taking on that indefinite liability here, at least in the United States.' The specialized formulas, which are generally given in hospitals, represent a very small portion of Abbott's overall sales. Though Mar's case was supposed to be the first one to go to trial in federal court, three other cases about the issue have already been heard in state courts. One of those cases resulted in a verdict of $60 million against Mead Johnson and another ended with a $495 million verdict against Abbott Laboratories — an outcome Abbott is appealing. In the third case, Abbott initially prevailed, with a jury deciding Abbott and Mead Johnson were not liable for a boy developing NEC after he was fed the companies' cow's milk-based products for premature infants. But in a setback for Abbott and Mead Johnson, a St. Louis judge in March granted a motion for a new trial citing 'errors and misconduct' in the original trial.
Chicago Tribune
05-05-2025
- Business
- Chicago Tribune
Judge throws out case against Abbott Laboratories over its preterm baby formula, days before trial was set to begin in Chicago
In a win for Abbott Laboratories, a federal judge in Chicago sided with the company Friday in the case of a woman who alleged that Abbott's formula for preterm infants led to her daughter's death. The case had been scheduled to go to trial this week, and was supposed to be the first to be heard in federal court in Chicago over the issue of whether Abbott's specialized cow's milk-based formula for preterm babies causes a life-threatening intestinal disease called necrotizing enterocolitis (NEC). North suburban-based Abbott and formula-maker Mead Johnson are facing hundreds of lawsuits in federal court in Chicago over the issue, and Abbott is facing more than 1,400 lawsuits total in courts across the country. The case dismissed Friday was a bellwether case, meaning its outcome was meant to help determine how the hundreds of other cases in federal court in Chicago proceeded, and/or how to settle those cases. The court is still scheduled to hear three other bellwether cases about the issue, with the next trial slated to begin in August. An Abbott spokesperson declined to comment Monday. An attorney for the plaintiff did not immediately respond to a request for comment Monday. In the case, Kentucky woman Ericka Mar contended that her daughter RaiLee, who was born at 28 weeks gestation in 2014, died when she was about 2 weeks old after being fed a cow's milk-based product made by Abbott. Mar alleges in her lawsuit that the formula was defective or unreasonably dangerous, that Abbott was negligent in selling it and that Abbott failed to warn health care providers and consumers of its dangers. But on Friday, U.S. District Court Judge Rebecca Pallmeyer granted Abbott's request for summary judgment and sided with the company. In her order, Pallmeyer wrote that Mar had not been able to present evidence that Abbott could have designed the formula differently to be safer, nor that her daughter's illness would have been prevented if Abbott had provided warnings about the higher risk of NEC in preterm babies who consume cow's milk-based formulas. Pallmeyer wrote that her decision in the case has 'limited direct application' to the hundreds of other cases against the formula-makers in federal court in Chicago. She wrote that it's possible plaintiffs in those other cases will be able to overcome the issues that led her to rule in favor of Abbott, depending on what evidence and testimony they provide. In a bright spot for the other cases, Pallmeyer also decided Friday to deny Abbott's request to exclude from those cases testimony from two expert witnesses on the link between cow's milk-based formulas and NEC. And she denied Abbott's motion for summary judgment in the other cases. Wells Fargo analysts said in a note Sunday that their legal consultant 'believes that it is likely that most, if not all, of the pending cases will fail on these same theories,' though it's possible different state laws might give other plaintiffs more 'breathing room,' the analysts wrote. The ruling on Friday was the latest twist in a yearslong legal battle between Abbott and families of babies who became ill after consuming the company's specialized formula for preterm infants — a battle that has potential implications for both Abbott and families with babies born very prematurely. Research has shown that formula feeding is associated with higher rates of NEC for premature infants, but that's not to say that cow's milk-based formulas cause the disease. Some premature babies who are fed only breast milk also develop NEC. Last year, three major federal agencies — the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health — released a statement saying, 'There is no conclusive evidence that preterm infant formula causes NEC.' Some medical professionals are concerned about the many cases against Abbott and Mead Johnson, saying juries should not be deciding questions that scientists can't even answer. They also worry that large verdicts against Abbott could lead the company to pull its cow's milk-based products for preterm infants off the market, leaving some families who depend on the products in a bind. Though neonatologists agree that mothers' breast milk should always be the first choice of nutrition for babies born very prematurely, it's not always available, and donated breast milk is not always an option. Abbott Chairman and CEO Robert Ford warned in an earnings call last year, 'If the regulatory process is disregarded, if the science is disregarded, it's going to be very difficult for any company to remain on the market with these products, taking on that indefinite liability here, at least in the United States.' The specialized formulas, which are generally given in hospitals, represent a very small portion of Abbott's overall sales. Though Mar's case was supposed to be the first one to go to trial in federal court, three other cases about the issue have already been heard in state courts. One of those cases resulted in a verdict of $60 million against Mead Johnson and another ended with a $495 million verdict against Abbott Laboratories — an outcome Abbott is appealing. In the third case, Abbott initially prevailed, with a jury deciding Abbott and Mead Johnson were not liable for a boy developing NEC after he was fed the companies' cow's milk-based products for premature infants. But in a setback for Abbott and Mead Johnson, a St. Louis judge in March granted a motion for a new trial citing 'errors and misconduct' in the original trial.
San Francisco Chronicle
04-05-2025
- Politics
- San Francisco Chronicle
Did S.F. moderates ‘rile up' Chinese Americans on recalls only to abandon them?
It was billed as a press conference by the Chinese American Democratic Club, but it was more of an unload session on San Francisco Supervisor Joel Engardio, whom the group is trying to recall. The anger was palpable from those speaking at the April 22 event who repeatedly called Engardio a 'liar' who failed to represent his constituents in the Sunset District. 'We have to recall this man and get us a person that truly represents the Sunset,' small-business owner and club member Albert Chow said. At issue: the permanent, 24/7 closure of the Upper Great Highway to car traffic. Chinese American Democratic Club members said Engardio betrayed and surprised them by becoming the lead proponent for closing the Great Highway after earlier supporting a 2021 compromise worked out by his predecessor, Gordon Mar, for reopening the road to cars on weekdays after it had been closed during the pandemic. 'Supervisor Joel Engardio has shown us time and time again that he isn't a leader,' Chinese American Democratic Club spokesperson Julia Quon said. If that rhetoric sounds familiar, it should. West side voters, many of them Chinese American, were a driving force behind recalls of San Francisco District Attorney Chesa Boudin and three school board members in 2022. The Chinese Democratic Club, a citywide organization, endorsed both recalls. Most of these same voters put their trust in Engardio, who supported the recalls; the more progressive Mar did not. Engardio rode this populist wave to a slim victory over Mar in 2022 in the District 4 race. It was an election year that was also a referendum on San Francisco's liberal politics, with the recalls generating millions from wealthy political donors seeking to push the city's government to the political center. Now Engardio is the target of a populist revolt, though it's not drawing the same political firepower as the Boudin and school board recalls. 'You would have hundreds of thousands of dollars, if not a million bucks, going into the effort to recall a progressive-leaning supervisor,' said political consultant David Ho, who worked on Mar's campaign. The campaign opposed to Engardio's recall received $382,325 in donations this year through April 15, including $125,000 from Yelp CEO Jeremy Stoppleman; the recall signature drive campaign has received $67,535 during the same period, according to city political campaign disclosure records. Ho said it's troubling to see tech oligarchs and other big political donors 'rile up' Chinese Americans for the district attorney and school board recall but not support the community on other issues. 'Money-wise, yeah, we're not pulling in the $300,000, $400,000 that Joel is,' Vin Budhai, a lead recall campaign organizer, said in an interview. 'But people-wise, that's what this campaign is built on, volunteer power, and it's working.' Recalling Engardio is an effort run by 'volunteers for and by District 4 residents' and 'that sort of funding from our local community is just as important,' Quon said in an interview. Politically, however, this recall effort is different: Keeping Engardio on the Board of Supervisors maintains the moderate majority that's been crafted in the past few elections, which is probably why many of the groups that backed previous recall efforts have stayed quiet or are supporting Engardio. 'Ideologically, Supervisor Engardio has been aligned with groups like ours and with many other more moderate political organizations out there,' said Cyn Wang, a board member of the Westside Family Democratic Club, which opposes the recall and endorsed Prop K. Wang co-founded the club after the Boudin and school board recalls, which she supported and said galvanized many club members to get involved in politics. Wang said Engardio is 'an ally to us' and disagreeing with his support for Prop K 'doesn't rise to the level of a recall.' The fight over the Great Highway shares similarities to political battles from two decades ago when the elevated Embarcadero and Central freeways were torn down over the opposition of many Chinese Americans in Chinatown and the west side over concerns about neighborhood access and traffic. 'That was sort of the first time that west side Chinese organized and actually flexed their muscle at the ballot box,' Ho said. 'But ultimately they did lose.' Several speakers at the Chinese American Democratic Club's press conference echoed the past feelings of being ignored, saying the recall was a way to make their concerns heard by their representatives. Until Prop K, it didn't seem like Engardio could draw much scorn. He's mostly worked to support issues important to his constituents, like bringing algebra classes back to middle schools. The Sunset Night Market he championed has been popular, and he's worked to address homelessness and crime in the neighborhood. 'I don't think he predicted such a strong outcome against leading the effort' on Prop K, Ho said. The campaign to oust Engardio has until May 22 to gather 10,000 signatures of District 4 residents to place a recall measure on the November ballot. If it makes the ballot and Engardio is voted out, Mayor Daniel Lurie would choose someone to fill the remainder of the term, which ends in January 2027. If that happens, all the anger will just give District 4 residents a new supervisor a year earlier than otherwise possible, and the newly named Sunset Dunes Park will still be there on the closed Great Highway. I don't agree with many of my neighbors and support closing the Great Highway, and I worry that the recall will be a waste of their growing political capital. Recall proponents say they want a supervisor who will represent the community's interests. About 40% of the west side's population is Asian American, mostly Chinese. Instead of being just used as a political cash 'ATM,' as Ho put it, let's get more Asian American candidates, who have been in short supply lately, running for office — moderates, progressives and even conservatives. That's more democratic than a recall.
Reuters
02-05-2025
- Health
- Reuters
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease
May 2 (Reuters) - A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories (ABT.N), opens new tab and Reckitt Benckiser (RKT.L), opens new tab subsidiary Mead Johnson for premature babies can cause a fatal intestinal illness, as the companies face hundreds of lawsuits over the claims. U.S. District Judge Rebecca Pallmeyer in Chicago said she will allow the experts to testify in future trials over claims that cow's milk-based formulas made by Abbott and Mead Johnson cause the illness in some premature babies. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. But in a separate order issued on Friday, Pallmeyer sided with Abbott in a lawsuit that was the first one slated to go to trial next week in federal court out of more than 700 similar cases that have been centralized in her court. The judge said the family of RaiLee Mar, an infant who was born prematurely and died of necrotizing enterocolitis after receiving some of Abbott's formula, had failed to show that the company's alleged failure to warn doctors and Mar's family about the risks of the disease was the cause of Mar's illness or that there was a reasonable alternative way the formula could have been made. Representatives for Abbott and Mead Johnson did not immediately respond to requests for comment. All of the lawsuits allege that the companies failed to warn that their specialized formulas used by newborn intensive care units in hospitals could cause necrotizing enterocolitis, a disease that almost exclusively affects premature infants and has an estimated mortality rate of more than 20%. The companies have denied the claims, saying that while breast milk protects against NEC, formula does not cause it, and that the benefits of breast milk have long been known to clinicians. In addition to the federal cases, both companies face hundreds of state court cases around the country, which have already resulted in verdicts of $60 million against Abbott and $495 million against Mead Johnson. Both companies prevailed in the most recent trial, in November. However, the judge in that case in March ordered a new trial, finding that lawyers for the defendants had acted improperly. The litigation has raised alarm from many doctors who say it could threaten the formulas' availability or affect medical decisions. The American Academy of Pediatrics recently filed a brief supporting Abbott in its appeal of the verdict against it last year, saying that formula is part of the standard of care for premature babies. U.S. regulatory agencies and a working group of scientists convened by the National Institutes of Health said in a joint report last year that current evidence does not support the hypothesis that formula causes necrotizing enterocolitis.
